Charles Schwab Portfolio holdings
Charles Schwab Corporation, founded in 1971 by Charles R. Schwab and headquartered in Westlake, Texas, is a leading financial services firm that revolutionized retail investing by offering low-cost brokerage services. Initially disrupting the industry with discount commissions, it has grown into a powerhouse providing a wide array of services, including trading platforms, robo-advisors, retirement accounts, and banking products, managing hundreds of billions in client assets. Known for its user-friendly technology and customer-centric approach, Schwab caters to individual investors, financial advisors, and institutions, notably expanding through its 2020 acquisition of TD Ameritrade. With a mission to democratize investing, Charles Schwab remains a dominant force in the shift toward accessible, self-directed wealth management.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$2.16B |
| 2 |
Hershey
HSY
|
+$663M |
| 3 |
Lockheed Martin
LMT
|
+$622M |
| 4 |
Altria Group
MO
|
+$525M |
| 5 |
Pfizer
PFE
|
+$499M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$2.76B |
| 2 |
Merck
MRK
|
+$2.35B |
| 3 |
Automatic Data Processing
ADP
|
+$1.57B |
| 4 |
Blackstone
BX
|
+$1.38B |
| 5 |
Illinois Tool Works
ITW
|
+$1.13B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.85% |
| 2 | Financials | 12.71% |
| 3 | Healthcare | 11.72% |
| 4 | Consumer Discretionary | 10.09% |
| 5 | Industrials | 9.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2126
N-able
NABL
$953M
| $7.53M | ﹤0.01% |
575,858
+29,223
| +5% | +$387K |
|
2127
Star Bulk Carriers
SBLK
$3.2B
| $7.51M | ﹤0.01% |
314,574
+29,360
| +10% | +$665K |
|
|
SHYF
2128
DELISTED
The Shyft Group
SHYF
| $7.49M | ﹤0.01% |
603,181
+88,964
| +17% | +$992K |
|
2129
Gorman-Rupp
GRC
$2.19B
| $7.46M | ﹤0.01% |
188,565
-127,892
| -40% | -$4.57M |
|
2130
Amneal Pharmaceuticals
AMRX
$6.02B
| $7.46M | ﹤0.01% |
1,230,334
-99,174
| -7% | -$559K |
|
2131
Pacific Biosciences
PACB
$441M
| $7.45M | ﹤0.01% |
1,987,519
+20,682
| +1% | +$121K |
|
2132
Methode Electronics
MEI
$499M
| $7.45M | ﹤0.01% |
611,471
+56,567
| +10% | +$1.07M |
|
2133
Arcutis Biotherapeutics
ARQT
$3.24B
| $7.44M | ﹤0.01% |
750,724
+179,406
| +31% | +$1.34M |
|
2134
CG Oncology
CGON
$6.1B
| $7.43M | ﹤0.01% |
+169,352
| New | +$6.92M |
|
2135
Quanterix
QTRX
$175M
| $7.43M | ﹤0.01% |
315,383
+19,572
| +7% | +$485K |
|
2136
Viridian Therapeutics
VRDN
$2.13B
| $7.43M | ﹤0.01% |
424,085
+52,774
| +14% | +$1.02M |
|
|
DENN
2137
DELISTED
Denny's
DENN
| $7.42M | ﹤0.01% |
828,325
+35,593
| +4% | +$349K |
|
2138
Douglas Dynamics
PLOW
$972M
| $7.4M | ﹤0.01% |
306,643
+17,621
| +6% | +$446K |
|
2139
National Presto Industries
NPK
$967M
| $7.39M | ﹤0.01% |
88,203
+992
| +1% | +$78.4K |
|
2140
Hanmi Financial
HAFC
$949M
| $7.38M | ﹤0.01% |
463,772
-442,623
| -49% | -$7.21M |
|
2141
Seneca Foods Class A
SENEA
$1.15B
| $7.38M | ﹤0.01% |
129,720
+8,174
| +7% | +$425K |
|
2142
AstraZeneca
AZN
$245B
| $7.38M | ﹤0.01% |
54,453
-19,173
| -26% | -$2.54M |
|
2143
Genco Shipping & Trading
GNK
$1.14B
| $7.37M | ﹤0.01% |
362,634
+38,947
| +12% | +$720K |
|
2144
Diebold Nixdorf
DBD
$2.63B
| $7.37M | ﹤0.01% |
213,865
+6,149
| +3% | +$197K |
|
|
ETNB
2145
DELISTED
89bio
ETNB
| $7.32M | ﹤0.01% |
629,233
+129,880
| +26% | +$1.44M |
|
|
PYCR
2146
DELISTED
Paycor HCM, Inc. Common Stock
PYCR
| $7.32M | ﹤0.01% |
376,641
+15,019
| +4% | +$300K |
|
|
GDEN
2147
DELISTED
Golden Entertainment
GDEN
| $7.32M | ﹤0.01% |
198,779
+26,575
| +15% | +$984K |
|
|
HAYN
2148
DELISTED
Haynes International, Inc.
HAYN
| $7.28M | ﹤0.01% |
121,009
+15,872
| +15% | +$914K |
|
|
SAGE
2149
DELISTED
Sage Therapeutics
SAGE
| $7.25M | ﹤0.01% |
387,139
-26,766
| -6% | -$617K |
|
|
DSKE
2150
DELISTED
Daseke, Inc. Common Stock
DSKE
| $7.25M | ﹤0.01% |
873,520
-2,158,515
| -71% | -$17.7M |
|
Similar funds
Charles Schwab's Q1 2024 Portfolio in Review
As of Q1 2024, Charles Schwab held 3,573 positions worth $433B, up 10% from $394B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Trading was light in Q1 2024: portfolio turnover was 3.8%. Charles Schwab opened 35 new positions and exited 102, leaving the 3,573-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 23% a quarter earlier, followed by Financials and Healthcare.
- Charles Schwab's largest Q1 2024 buy was Schwab Fundamental US Large Company Index ETF: 3,608,604 shares worth $81.1M.
- Charles Schwab added most to Bristol-Myers Squibb in Q1 2024, an estimated $2.16B increase.
- Charles Schwab's biggest Q1 2024 reduction was Broadcom, cutting an estimated $2.76B.
- Charles Schwab fully exited Splunk Inc in Q1 2024, selling an estimated $104M.
- Charles Schwab's ten largest holdings make up 20% of its $433B portfolio in Q1 2024.
- Charles Schwab opened 35 new positions and closed 102 in Q1 2024.
- Charles Schwab's portfolio value rose 10% quarter-over-quarter to $433B.
Based on Charles Schwab's 13F filing for Q1 2024, filed 9 May 2024.